Balyasny Asset Management
IMNM icon

Balyasny Asset Management’s Immunome IMNM Stock Holding History

Balyasny Asset Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.5M Sell
251,396
-1,178,284
-82% -$26.2M 0.01% 1331
2025
Q4 		$30.7M Buy
+1,429,680
New +$25.1M 0.04% 524
2025
Q3 		– Sell
-109,754
Closed -$1.02M – 3168
2025
Q2 		$1.02M Buy
+109,754
New +$900K ﹤0.01% 2030
2024
Q3 		– Sell
-375,242
Closed -$4.54M – 2931
2024
Q2 		$4.54M Buy
375,242
+220,754
+143% +$3.45M 0.01% 1216
2024
Q1 		$3.81M Buy
154,488
+125,839
+439% +$2.55M 0.01% 1323
2023
Q4 		$307K Buy
+28,649
New +$238K ﹤0.01% 2151

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Balyasny Asset Management's IMNM Position: Q1 2026 in Review

Balyasny Asset Management reduced its Immunome (IMNM) stake by 82% in Q1 2026, selling an estimated $26.2M and leaving 251,396 shares worth $5.5M. The position accounts for 0.01% of the portfolio, ranked #1331.

Balyasny Asset Management first reported a position in IMNM in Q4 2023 and has held it in 6 quarters since. The position peaked at $30.7M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Balyasny Asset Management held 251,396 shares of Immunome worth $5.5M as of Q1 2026.
  • Balyasny Asset Management sold 1,178,284 Immunome shares in Q1 2026, an estimated $26.2M.
  • Immunome made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1331 holding.
  • Balyasny Asset Management first reported a position in Immunome in Q4 2023 and has held it in 6 quarters since.
  • Balyasny Asset Management's Immunome position peaked at $30.7M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.